Ludovic Helfgott

EVP & Head of Biopharm at Novo Nordisk

Mr Helfgott joined Novo Nordisk from AstraZeneca, where he was global vice president in charge of the company's Cardiovascular, Metabolism and Renal global franchise, supervising both assets in development and on the market. He joined AstraZeneca in 2005 in an international sales effectiveness role and has since held operational leadership roles with increasing responsibilities in Italy, Spain and at corporate headquarters. Prior to this, Mr Helfgott was with McKinsey & Company, in Paris, Moscow and Brussels from 1998 to 2005.

Mr Helfgott holds an M.B.A. from Insead, France, 2001, and is a graduate of the French Army Officer’s Academy, E.A.A.B.C, France, 1998. Moreover, Mr Helfgott holds an M.A. in Finance & Laureate of the Health Economy Chair, E.S.S.E.C, France, 1996, and an M.A. in Political and Macroeconomy, I.E.P. Paris, France, 1994.

Links

Previous companies

AstraZeneca logo
McKinsey & Company logo

Timeline

  • EVP & Head of Biopharm

    April 1, 2019 - present

View in org chart